Long-term prognostic value of growth differentiation factor-15 in acute coronary syndromes

Peiró, Óscar M.; García-Osuna, Álvaro; Ordóñez-Llanos, Jordi; Cediel, Germán; Bonet, Gil; Rojas, Sergio; Quintern, Verónica; Bardajı́, Alfredo

doi:10.1016/j.clinbiochem.2019.07.014

Cited by 10 publications

(4 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is why GDF15 has many other names, such as NSAID-activating gene 1 (NAG-1) [9], macrophage inhibitory cytokine 1 (MIC-1) [1], and prostate-derived factor (PDF) [10]. Under pathological conditions, the serum level of GDF15 can increase in tumors, diabetes, cardiovascular diseases, mitochondrial damage, and other diseases [11][12][13][14].…”

Section: The Relationship Between Gdf15 and Weight Changementioning

confidence: 99%

Research Progress on the Role and Mechanism of GDF15 in Body Weight Regulation

Dong,

2023

Obes Facts

View full text Add to dashboard Cite

Background: Growth differentiation factor-15 (GDF15) is a member of the growth differentiation factor subfamily in the transforming growth factor beta superfamily. GDF15 has multiple functions and can regulate biological processes. High levels of GDF15 in the circulation can affect metabolic processes. Studies have shown that GDF15 is associated with changes in body weight. Summary: This review reviews the current knowledge on the relationship between GDF15 and body weight change, focusing on the role and mechanism of GDF15 in body weight regulation. GDF15 plays an important role in reducing food intake, improving insulin resistance, and breaking down fat, suggesting that GDF15 has an important regulatory effect on body weight. The mechanism by which GDF15 causes reduced food intake may be related to changes in food preference, delayed gastric emptying, and conditioned taste aversion. GDF15 can combat insulin resistance induced by inflammation or protect β cell from apoptosis. GDF15 probably promotes lipolysis through a brain-somatic tissue circuit. Several factors and related signaling pathways are also mentioned that can contribute to the effects of GDF15 on reducing weight. Key Message: GDF15 plays an important role in weight regulation and provides a new direction for the treatment of obesity. Its effects on resisting obesity are of great significance to inhibiting the progression of metabolic diseases. It is expected to become a new target for regulating body weight, improving obesity, and treating metabolic diseases such as diabetes.

show abstract

Section: The Relationship Between Gdf15 and Weight Changementioning

confidence: 99%

Research Progress on the Role and Mechanism of GDF15 in Body Weight Regulation

Dong,

2023

Obes Facts

View full text Add to dashboard Cite

show abstract

“…GDF-15 is increased in response to cardiac damage and the inflammatory process, thereby increasing the risk of an elevated cardiovascular event [ 177 ]. In the presence of an ACS, a single measurement of GDF-15 and concentrations greater than 1800 ng/L were linked to an elevated risk of all-cause mortality, MACEs and hospitalization for heart failure, but not subsequent readmission for MI [ 178 , 179 ]. Additionally, GDF-15 concentrations were assessed at baseline in 4330 patients, and the same cut-off value was linked to a twofold increase in the risk of CV death/HF [ 180 ].…”

Section: Resultsmentioning

confidence: 99%

From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction

Stătescu

Anghel

Tudurachi

et al. 2022

IJMS

View full text Add to dashboard Cite

Despite all the important advances in its diagnosis and treatment, acute myocardial infarction (AMI) is still one of the most prominent causes of morbidity and mortality worldwide. Early identification of patients at high risk of poor outcomes through the measurement of various biomarker concentrations might contribute to more accurate risk stratification and help to guide more individualized therapeutic strategies, thus improving prognoses. The aim of this article is to provide an overview of the role and applications of cardiac biomarkers in risk stratification and prognostic assessment for patients with myocardial infarction. Although there is no ideal biomarker that can provide prognostic information for risk assessment in patients with AMI, the results obtained in recent years are promising. Several novel biomarkers related to the pathophysiological processes found in patients with myocardial infarction, such as inflammation, neurohormonal activation, myocardial stress, myocardial necrosis, cardiac remodeling and vasoactive processes, have been identified; they may bring additional value for AMI prognosis when included in multi-biomarker strategies. Furthermore, the use of artificial intelligence algorithms for risk stratification and prognostic assessment in these patients may have an extremely important role in improving outcomes.

show abstract

“…Continuous measurement of GDF-15 can reflect the ongoing inflammatory response during cardiac remodeling. A follow-up study [27] involving 358 ACS patients over a period of more than 6 years revealed a significant increase in all-cause mortality, MACE, and the risk of hospitalization for heart failure when the GDF-15 concentration exceeded 1800 ng/L. Moreover, higher levels of GDF-15 were consistently associated with an increased prevalence of cardiovascular risk factors, a history of cardiovascular disease, and adverse outcomes during admission.…”

Section: The Prognostic Value Of Gdf-15 In Acs Patientsmentioning

confidence: 99%

Research Status of Growth Differentation Factor-15 in Acute Coronary Syndrome

2024

FMSR

View full text Add to dashboard Cite

Acute coronary syndrome (ACS) is a group of clinical syndromes caused by acute myocardial ischemia, including ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). Currently, the clinical diagnosis of ACS relies on three key factors: clinical data (such as medical history, age, symptoms, etc.), electrocardiogram (ECG), and cardiac biomarkers (cTn, MyO, CK-MB, NT-proBNP, etc.). However, diagnosing UA patients and some NSTEMI patients can be challenging due to the absence of characteristic electrocardiogram dynamic evolution seen in STEMI patients. This is particularly true in cases with mild symptoms or no obvious chest pain and negative detection of myocardial injury markers. Recent studies have highlighted the potential clinical value and availability of growth differentiation factor 15 as a new cardiac biomarker closely associated with the occurrence and prognosis of ACS [1]. However, further investigation is needed to fully understand its role in ACS. This article aims to review the clinical application value of GDF-15 in acute coronary syndrome.

show abstract

Long-term prognostic value of growth differentiation factor-15 in acute coronary syndromes

Cited by 10 publications

References 39 publications

Research Progress on the Role and Mechanism of GDF15 in Body Weight Regulation

Research Progress on the Role and Mechanism of GDF15 in Body Weight Regulation

From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction

Research Status of Growth Differentation Factor-15 in Acute Coronary Syndrome

Contact Info

Product

Resources

About